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Abstract: Infections caused by multidrug resistant Salmonella strains are problematic in swine and
are entering human food chains. Bacteriophages (phages) could be used to complement or replace
antibiotics to reduce infection within swine. Here, we extensively characterised six broad host range
lytic Salmonella phages, with the aim of developing a phage cocktail to prevent or treat infection.
Intriguingly, the phages tested differed by one to five single nucleotide polymorphisms. However,
there were clear phenotypic differences between them, especially in their heat and pH sensitivity.
In vitro killing assays were conducted to determine the efficacy of phages alone and when combined,
and three cocktails reduced bacterial numbers by ~2 × 103 CFU/mL within two hours. These
cocktails were tested in larvae challenge studies, and prophylactic treatment with phage cocktail
SPFM10-SPFM14 was the most efficient. Phage treatment improved larvae survival to 90% after 72 h
versus 3% in the infected untreated group. In 65% of the phage-treated larvae, Salmonella counts
were below the detection limit, whereas it was isolated from 100% of the infected, untreated larvae
group. This study demonstrates that phages effectively reduce Salmonella colonisation in larvae,
which supports their ability to similarly protect swine.
Keywords: Salmonella phages; phage cocktails; phage therapy; phage characterisation; larvae
infection model; single nucleotide polymorphisms
1. Introduction
Non-typhoidal Salmonella spp. are a major cause of foodborne gastroenteritis world-
wide, causing 155,000 diarrheal related deaths annually [1,2]. In the United Kingdom
alone, the bacterium is responsible for 33,000 human infections each year [3], and, on
average, 11.7% of these Salmonella infections are linked to the ingestion of contaminated
pork products [4]. However, using antibiotics to treat and reduce Salmonella infections in
pigs is becoming increasingly difficult, as disease-causing strains are often resistant to the
most common antimicrobials used in veterinary practice [5–7]. Consequently, multidrug
resistant (MDR) Salmonella strains have entered the human food chain and are posing a
major health threat [8]. Novel antimicrobials are needed to help treat and control the spread
of Salmonella from pigs to humans [9].
One promising alternative is the use of bacteriophages (phages), viruses that target and
kill bacteria [10,11]. Several studies have shown that phage therapy in pigs is effective and
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can significantly reduce Salmonella colonisation both pre- [12–18] and post-slaughter [19–21].
However, although these studies show great potential for phages to be used in swine, the
phages used in the experiments were not fully characterised. In all cases, either genetic
data needed to establish that phages are lytic, or phenotypic data such as host range to
show if phages lyse representative strains from Salmonella serotypes associated with pigs,
or both data sets were not presented within the context of efficacy trial data. Furthermore,
existing studies did not investigate phage resilience to environmental factors, such as
pH and temperature, which is needed to optimise phage formulations for delivery. For
example, if phages are added to animal feed they need to survive temperatures above
55 ◦C for at least twenty minutes potentially up to an hour, dependent on the mill used
during the feed pelleting process [22]. In addition, phages could be delivered to pigs via
their addition to drinking water and for this it would need to be determined how stable
phages are at ambient temperatures and in water. The pH stability is also important to
consider as gastrointestinal pH changes could affect phage activity, which in pigs can
range between pH 1.8 and pH 8 [23,24]. Finally, further data are needed on whether the
phages kill bacteria equally efficiently when used individually or as phage cocktails. Such
detailed phage characterisation is needed to improve our understanding of Salmonella
phages and has been conducted for other phages, such as for phages infecting Ralstonia
solanacearum [25] and for a collection of phage isolated from sewage [26].
As Galleria mellonella larvae have a similar innate immune response as larger verte-
brates [27,28], they have been successfully used to test efficacy of phage lysis in vivo [29–32].
The infection model is both simpler and cheaper and requires a less complex ethical frame-
work than mammalian studies [33], allowing a larger number of formulations, doses and
treatment regimens to be tested [34].
This study addresses the generation of phenotypic characterisation data needed for
Salmonella phage development. We investigate phenotypic behaviour and efficacy against
Salmonella for phages used individually and when combined in phage cocktails. We in-
vestigated six lytic phages SPFM2, SPFM4, SPFM10, SPFM14, SPFM17 and SPFM19 from
our Salmonella phage collection, which are 99% similar to each other based on average
nucleotide identity (ANI0). All six phages are lytic based on the absence of any known
lysogeny associated genes identified in the phage genomes, they are members of Myoviridae
family within Caudovirales, and based on the genome data, they are part of the Seoulvirus
genus [35]. The phages were selected for the study as they have broad host ranges and
lyse 98–100% of MDR screened Salmonella strains that are representative of the top five
serotypes associated with pigs (n = 67) [35]. The phages were characterised according to
their burst sizes, pH and temperature sensitivity and their bacterial host receptors. Pheno-
typic differences between the phages were identified, and, subsequently, single-nucleotide
polymorphism (SNP) analysis between the phages was conducted to determine if genetic
differences can be linked to their phenotypes. To identify optimal phage combinations,
killing assay experiments were conducted in vitro and the efficacy of the three best combi-
nations were tested as phage cocktails in challenge larvae studies. This paper showcases
data on stability and efficacy of Salmonella phage cocktails.
2. Results
2.1. Phenotypic Parameters of Lifecycle
One step growth curves were carried out on phages: SPFM2, SPFM4, SPFM10, SPFM14,
SPFM17 and SPFM19, all of which have a mean burst size of 164 ± 30 PFU/cell. SPFM10
and SPFM17 have a latent period of 20 min and the other phages have latent periods of
~30 min (Supplementary Table S1).
2.2. Temperature and pH Stability of Phages
To determine virion heat sensitivity, phages were exposed for one hour to temperatures
ranging from 4 to 100 ◦C (Figure 1a). One hour was selected on the basis that when phages
are added to feed they would be exposed to high temperatures during the milling process
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for up to an hour [22,36]. All phages were stable up to 50 ◦C; SPFM10 and SPFM17 survived
at 60 ◦C and SPFM10 showed no significant drop in titre even at 80 ◦C. At 90 ◦C the titre
of SPFM10 reduced from 8 × 108 PFU/mL to 6 × 104 PFU/mL. No viable phage particles
were recovered at 100 ◦C. To verify the heat stability of SPFM10 at 90 ◦C, the phage was
incubated in two different temperature-controlled devices: a heat block and a water bath.
In both cases, the results were not significantly different (p > 0.05), thus confirming the
heat stability.
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incubation at pH 3 reduced the titre of SPFM10 to 1.5 × 102 PFU/mL, and SPFM14 and 
SPFM17 to 3.5 × 105 PFU/mL. 
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temperatures (a) and pH (b). Stability of phage SPFM2 is shown in blue, SPFM4 in purple, SPFM10
in red, SPFM14 in green, SPFM17 in orange and SPFM19 in grey. Data presented are the average from
three biological replicates, each with three technical repeats. Error bars represent the standard error
of the mean (SEM).
The phage set was exposed to a range of different pH values to determine their sensi-
tivity (Figure 1b), to establish how sensitive the phages would be to pig pH gastrointestinal
changes. No phages survived at or below pH 2 or above pH 13. SPFM2, SPFM4 and
SPFM19 were stable between pH 3 to 12. SPFM10, SPFM14 and SPFM17 were stable be-
tween pH 4–12 and average phage titres remained at the initial 8 × 108 PFU/mL. However,
incubation at pH 3 reduced the titre of SPFM10 to 1.5 × 102 PFU/mL, and SPFM14 and
SPF 17 to 3.5 × 105 PFU/mL.
2.3. Identification of the Bacterial Receptor
To determine the bacterial receptors for the six phages, their efficiency of plating
(EOP) was tested on different mutant strains of Salmonella strain SL1344 (Table 1. The
EOP is a comparison of the phage titre on different strains versus the phages titre on the
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propagation strain, which is the wild-type SL1344 strain. All phages infected strains with
deletion in the flagellar production gene (flgK) and in the gene butB which encodes the
vitamin B12 uptake outer membrane protein [37], as effectively as the wild-type strain
SL1344. In contrast, the strain, which had a mutation in rfaL, the gene involved in the
LPS-related O-antigen production, did not support adsorption or infection and EOP was
0% for all phages (Table 1). This suggests the phages are using a component on LPS as their
bacterial receptor.
Table 1. EOP on wild-type SL1344 strain versus receptor mutant strains of SL1344.
Efficiency of Plating 1
Phages SL1344 ∆butB SL1344 ∆flgK SL1344 ∆rfaL
SPFM2 1.00 0.99 0
SPFM4 0.99 1.00 0
SPFM10 0.98 1.00 0
SPFM14 1.00 1.00 0
SPFM17 0.99 1.00 0
SPFM19 1.00 1.00 0
1 Plaquing efficiencies of 1.00 show there is no difference in EOP on the wild-type strain versus the mutant strain.
2.4. Genetic Differences between the Six SPFM Phages
Previous analysis suggested that the phages are 99% genetically similar to each other
based on ANI [35], but, intriguingly, our results show there are clear phenotypic differences
between them. The high sequence conservation between the phages allowed us to identify
SNPs that are likely to be linked to these phenotypic differences.
SNP analysis was conducted by comparing the genome of SPFM10 with the clear
heat stable phenotype to SPFM2, 4, 14, 17 and 19. There were five SNPs between SPFM10
and the other phages (Table 2 and Supplementary Table S2). One SNP in the genome
of SPFM10, which is distinct from the other phages is at position 70,890 bp (locus tag
SPFM10_00081), which causes the amino acid change from threonine to serine and results
in a non-synonymous change. Further evidence that this SNP confers heat stability can be
seen from the observation that this is the only SNP between phages SPFM10 and SPFM14
(a phage with standard heat sensitivity). The largest number of SNPs between SPFM10 and
the other phages in the set are seen when compared to SPFM17, five SNPs were identified
of which four caused a non-synonymous change and one caused a synonymous change
(locus tag SPFM10_00140 at position 113292 bp) (Table 2).
Table 2. Phage SPFM10 was compared to SPFM2, SPFM4, SPFM14, SPFM17 and SPFM19 to identify










70890 SPFM10_00081 Hypothetical protein A -> T Thr -> Ser 1.05 × 10−38
74294 SPFM10_00084 Hypothetical protein A -> C Ser -> Leu 1.70 × 10−43
74298 SPFM10_00084 Hypothetical protein G -> T Ser -> Leu 4.28 × 10−44
SPFM4
70890 SPFM10_00081 Hypothetical protein A -> T Thr -> Ser 2.20 × 10−144
74291 SPFM10_00084 Hypothetical protein A -> G Pro -> Leu 1.34 × 10−238
74295 SPFM10_00084 Hypothetical protein G -> T Ser -> Arg 3.22 × 10−247
SPFM14 70890 SPFM10_00081 Hypothetical protein A -> T Thr -> Ser 5.14 × 10−16











57985 SPFM10_00067 Chromosomepartition protein Smc A- > G Gin -> Arg 1.73 × 10
−49
70890 SPFM10_00081 Hypothetical protein A -> T Thr -> Ser 2.77 × 10−66
74291 SPFM10_00084 Hypothetical protein G -> A Pro -> Leu 6.66 × 10−94
74295 SPFM10_00084 Hypothetical protein T -> G Ser -> Arg 1.06 × 10−92
113292 SPFM10_00140 Hypothetical protein A -> G Cys -> Cys 1.10 × 10−65
SPFM19
70890 SPFM10_00081 Hypothetical protein A- > T Thr -> Ser 1.55 × 10−50
72949 SPFM10_00083 Hypothetical protein C -> T Ser -> Gly 1.74 × 10−52
1 Corresponding protein sequences from the genome of SPFM10 are listed in Supplementary Table S2.
2.5. Infection Dynamics of Six SPFM Phages In Vitro
In vitro killing assays were conducted on all phages to determine their individual
efficacy to lyse the MDR S. Typhimurium S01160-12 strain [38] and when combined as
two, three and four-phage cocktails. Phages within the cocktails tested were randomly
selected and thirty-six different combinations were tested. All killing assays were assessed
over a six hour time period, at a multiplicity of infection (MOI) of 100 to maximise lysis of
the target strain, which would help to identify the best phage and phage cocktails. Phage
infected CFU counts were compared to an uninfected bacterial control. Below, we discuss
CFU counts at one, two and six hours and the results of all phages and phage combinations
are discussed in comparison to the uninfected control. All data termed significant are
p < 0.05.
All phage cocktail combinations tested are listed in Table 3, and killing curves are
presented in Figure 2. For clarity, the killing assay results of the two and three phage
cocktails are separated in two graphs (Figure 2b–e). In Supplementary Table S3, the
average CFU counts are shown. Within the phage cocktails tested, there was a consistent
pattern observed with the total phage counts, where after two hours, the phage counts
had increased tenfold in comparison to the starting inoculum, indicating phage replication
had occurred.
Table 3. A list of phage and phage cocktails tested in in vitro killing assays.
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2.5.1. Bacterial killing Assays with Single Phage Suspensions
One hour post-infection, all single phages significantly reduced bacterial counts by
6.2 × 101 to 2 × 102 CFU/mL (Figure 2a). After two hours the average bacterial counts
were 1.3 × 109 CFU/mL in the uninfected bacterial culture. In comparison, addition of all
single phages significantly reduced bacterial counts. SPFM2, SPFM4, SPFM10 and SPFM19
reduced bacterial counts the most, to an average of 5.5 × 106 CFU/mL. After six hours
bacterial counts for cultures infected with SPFM14 and SPFM17 were similar to the bacterial
control but cultures infected with the other four phages remained significantly lower.
2.5.2. Efficacy of Multiple Phage Cocktails
All fifteen two-phage cocktail combinations reduced S. Typhimurium numbers be-
tween 1 × 101 and 1 × 103 CFU/mL one hour post-infection in comparison to the bacterial
control (Figure 2b,c). After two hours of incubation, all phage cocktails maintained signifi-
cant reductions in bacterial counts. Phage combinations SPFM2-SPFM4, SPFM2-SPFM10,
SPFM10-SPFM14, and SPFM10-SPFM17 all caused equally high reductions in bacterial
numbers two hours post-infection, where average bacteria counts were 4.5 × 104 CFU/mL
versus 1.3 × 109 CFU/mL for the bacterial control. At six hours, bacterial regrowth was
observed but was significantly lower than the control. Again, the same phage cocktails
were most efficient at reducing bacterial counts at six hours. The average bacterial counts
were 2.60 × 107 CFU/mL versus 2.50 × 109 CFU/mL for the control.
Eleven three-phage combinations were tested (Figure 2d,e) and all rapidly reduced bac-
terial numbers by ~3.2 × 102 CFU/mL one hour post-infection (Figure 2d,e). At two hours
post-infection, phage cocktails SPFM10-SPFM17-SPFM19 and SPFM2-SPFM10-SPFM19
equally caused the highest reductions of 3.6 × 105 CFU/mL versus 1.3 × 109 CFU/mL for
the bacterial control. At six hours post-infection, all phage cocktails maintained signifi-
cant reductions.
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Figure 2. Efficacy of ind vidual (a), t ,c), three (d,e) and four (f) phage cocktails at reducing an
MDR S01160-12 S. Typhimurium str in vitro. Bacterial cult res were infected with the differ nt
phage cocktails (a–f) at MOI of 100 bacterial counts (CFU/mL) were det rmined every hour for
6 h. Data presented are averages fro t ree biological repeats, each with three technical repeats and
error bars represent SEM.
Four four-phage cocktails were tested, and all caused rapid bacterial lysis with a
decrease of 3.2 × 101 to 3.2 × 102 CFU/mL one hour post-infection (Figure 2f). After two
hours p st-infec io three cocktails, namely, SPFM10-SPFM14-SPFM17-SPFM19, SPFM2-
SPFM10-SPFM14-SPFM19 and SPFM2-SPFM4-SPFM10-SPFM19, were equally the most
effective and reduced bacterial counts to 4 × 105 CFU/mL compared to ~1.3 × 109 CFU/mL
for the bacterial control. After six hours post-infection, all cocktails maintained signifi-
cant reductions.
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2.6. Infection Dynamics of Phage Cocktails In Vivo
The efficacy of the most effective in vitro phage cocktails were tested in the in vivo
G. mellonella larvae infection model; to determine if they had similar efficacy in a more
complex setting. The phage cocktails tested were SPFM10-SPFM14 (two-phage); SPFM4-
SPFM10-SPFM19 (three-phage) and SPFM2-SPFM10-SPFM14-SPFM19 (four-phage).
Two phage regimens were tested, to determine which most effectively reduced
Salmonella colonisation. The first was prophylactic phage administration one hour be-
fore larvae were infected with the MDR S. Typhimurium S01160-12 strain. The second was
concurrent administration of phage when larvae were infected with Salmonella (Table 4).
All challenge studies were conducted for 72 h, as after which the survival rate of challenged
larvae (C-6) dropped to 3%.
Table 4. The different larvae groups used to evaluate the effectiveness of phage therapy for the
treatment of challenged larvae.




C-3 Administered the 2-phage cocktail SPFM10-SPFM14
C-4 Administered the 3-phage cocktail SPFM4-SPFM10-SPFM19
C-5 Administered the 4-phage cocktail SPFM2-SPFM10-SPFM14-SPFM19
C-6 Challenged with Salmonella
Prophylactic phage treatments
P-2 Administered 2-phage cocktail SPFM10-SPFM14 one hour prior to challengewith Salmonella
P-3 Administered 3-phage cocktail SPFM4-SPFM10-SPFM19 one hour prior tochallenge with Salmonella
P-4 Administered 4-phage cocktail SPFM2-SPFM10-SPFM14-SPFM19 one hour priorto challenge with Salmonella
Co-infection studies
CoI-2 Administered 2-phage cocktail SPFM10-SPFM14 simultaneously with Salmonella
CoI-3 Administered 3-phage cocktail SPFM4-SPFM10-SPFM19 simultaneouslywith Salmonella
CoI-4 Administered 4-phage cocktail SPFM2-SPFM10-SPFM14-SPFM19simultaneously with Salmonella
1 In each group 60 larvae were used for the study. Every 24 h 20 larvae were checked for survival and culled to
enumerate PFU and CFU counts. 2 Phages, challenge with MDR S. Typhimurium S01160-12 strain and PBS were
administered orally.
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groups there were significant reductions in Salmonella numbers (p < 0.05) compared to
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100 CFU/larva) for 55%, 25% and 65% of larvae in groups P-2, P-3 and P-4, respectively
versus isolation of Salmonella from 100% of larvae in group C-6.
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with phage cocktails one hour prior to infection (a,c,e) or simultaneously administered phage and 
Salmonella (b,d,f). Figures (a,b) show survival of larvae over 72 h, boxplots (c,d) show changes in 
Salmonella counts and boxplots (e,f) show total phage counts of the phage cocktail. The larvae treat-
ment groups were: healthy larvae (orange lines), larvae administered PBS (grey lines), larvae only 
infected with Salmonella (black lines/bars); larvae administered the cocktail SPFM10-SPFM14 (red 
lines/bars); larvae administered the cocktail SPFM4-SPFM10-SPFM19 (blue lines/bars); and larvae 
administered the cocktail SPFM2-SPFM10-SPFM14-SPFM19 (green lines/bars). Error bars in graphs 
(c,d) show SEM and statistically significant differences between larvae infected with Salmonella only 
Figure 3. Efficacy of phage cocktails in challenged larvae studies. Larvae were infected with the
MDR S01160-12 S. Typhimurium strain at 105 CFU/larvae and were either prophylactically treated
with phage cocktails one hour prior to infection (a,c,e) or simultaneously administered phage and
Salmonella (b,d,f). Figures (a,b) show survival of larvae over 72 h, boxplots (c,d) show changes
in Salmonella counts and boxplots (e,f) show total phage c unts of the phage cocktail. The l rvae
treatment groups were: healthy larvae (orange lines), larvae administ re PBS (grey lines), larva
only infected with Salmonella (black lines/bars); larvae administered the cocktail SPFM10-SPFM14
(red lines/bars); larvae administered the cocktail SPFM4-SPFM10-SPFM19 (blue lines/bars); and
larvae administered the cocktail SPFM2-SPFM10-SPFM14-SPFM19 (green lines/bars). Error bars in
graphs (c,d) show SEM and statistically significant differences between larvae infected with Salmonella
only (black bars) and treated with phages is displayed on the graphs (ns > 0.05, * p ≤ 0.05, ** p ≤ 0.01
and *** p ≤ 0.001).
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After 72 h, in group C-6 the bacterial abundance was 3.5 × 106 CFU/larva and survival
rates dropped to 3%. In comparison the survival rates in P-2, P-3 and P-4 were 90%, 68%
and 62%, respectively and Salmonella counts were significantly lower than C-6 (p < 0.001).
Salmonella was not recovered for 70%, 50% and 65% of larvae in groups P-2, P-3 and P-4,
respectively, which suggests the phage treatments cleared infection in these larvae. In
comparison, Salmonella was isolated from 100% of larvae from group C-6.
In larvae groups P-3 and P-4, there was no increase in the phage titres over 72 h
(Figure 3e) and phage numbers were comparable to the larvae groups only administered
the respective phage cocktails (C-4 and C-5). In contrast, in the larvae group P-2 total
phage abundance was ten-fold lower in comparison to the phage control group (C-3).
However, after 48 h phage numbers increased ten-fold, suggesting active phage replication
had occurred.
2.6.2. Simultaneous Phage Treatment of Infected Larvae
Larvae co-infected with two (CoI-2), three (CoI-3) and four-phage (CoI-4) cocktails
had over 88% survival rates after 24 h, which was similar to the infected control group C-6
(Figure 3b,d; Table 4). There were, however, significant reductions in Salmonella abundance
in all larvae groups treated with phage cocktails, in comparison to C-6 (p ≤ 0.001).
After 48 h the survival rate of larvae in group C-6 dropped to 60%. In challenged,
phage treated groups CoI-2, CoI-3 and CoI-4, the survival rates were 84%, 72% and 78%, re-
spectively. This increased survival rate was reflected by significant reductions in Salmonella
counts per larva in all phage treated groups compared to C-6 (p < 0.001). Average Salmonella
counts were 7.4 × 102, 2.5 × 102, 7.5 × 101 and 4.0 × 106 CFU/larva for groups CoI-2,
CoI-3, CoI-4 and C-6, respectively. Salmonella was not isolated from 50%, 60% and 55%
larvae in groups CoI-2, CoI-3 and CoI-4, respectively.
After 72 h, all phage cocktails caused significant reductions in Salmonella (p < 0.001) in
comparison to group C-6. The survival rate of the C-6 also dropped to 3%, compared to
>65% in all phage treated groups (CoI-2, 3 and 4). In addition, Salmonella numbers were
below the detection limit and were not isolated from 65%, 70% and 60% larvae in groups
CoI-2, CoI-3 and CoI-4, respectively. Again, the data show phage treatment could clear
infection in challenged larvae. Phage numbers remained constant for all phage treatment
groups (Figure 3f) over 72 h, and there were no significant changes in phage numbers
compared to phage control groups (C-3, C-4 and C-5).
2.6.3. Sensitivity of Recovered Salmonella Colonies after Exposure to Phage Cocktails in a
Larvae Model
To determine if phage resistance evolves in G. mellonella, Salmonella colonies recovered
from infected larvae after 72 h were isolated and tested for susceptibility to phages they
had been subjected to. All colonies recovered from both dead and living larvae remained
sensitive to the phages (Supplementary data Tables S4–S6). For further analysis, ten
Salmonella colonies from each phage treatment were randomly selected and the EOP of the
individual phages within the cocktails was determined and compared to the wild-type
S. Typhimurium S01160-12 strain (Figure 4). EOP values were ~1.0, indicating EOP was the
same as on the wild-type strain and phage-resistant colonies were not isolated.
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3. Discussion
In this study, we fully characterised six broad host range phages with the aim of
developing a cocktail to prevent or treat Salmonella infection in pigs. All six phages have
similar burst sizes and use a component on the LPS as their bacterial receptor. However,
they are differentially sensitive to temperature and pH.
The temperature stability data showed the SPFM phages had distinct phenotypic dif-
ferences. All phages were stable at 50 ◦C, consistent with other characterised phages [39,40];
however, SPFM10 was significantly more stable, remaining active even after being exposed
to 90 ◦C for an hour. This is a very unusual phenotype, as, typically, when phages are
exposed to high temperatures, they lose infectivity [41]. Clearly, an increased heat stability
expands downstream phage applications as SPFM10 is likely to remain stable during spray
drying to make dry phage powders, which would improve shelf life [42–44].
Phages SPFM10, SPFM14 and SPFM17 were less stable at pH 3 than SPFM2, SPFM4
and SPFM19. The pH stability of phages impacts the delivery method used in pigs, as
if administered orally they will encounter acidic environments as they pass through the
digestive tract of the pig [45]. The SPFM phages all remained infective above pH 4, but at
lower pH, they may not survive the digestive tract in their native state. However, methods
are being developed to encapsulate phages in polymers, to improve their stability at lower
pH [46].
Ideally, phage or phage cocktails for therapeutic use will effectively eliminate multiple
strains of the target bacterial species and delay occurrence of phage-resistant mutants [47].
To identify such phage(s), we tested the activity of six SPFM phages alone and in combi-
nations in vitro. Phage cocktails were more effective than individual phages at bacterial
lysis and lowered the re-growth of S. Typhimurium compared to when individual phages
are used, presumably because there was less development of phage resistance. Thirty-six
different phage combinations were tested in vitro and their ability to reduce bacterial cell
numbers varied significantly. Although cocktails with three and four phages in were tested,
it was cocktails with only two phages (SPFM10-SPFM14 and SPFM2-SPFM10) that were
the most effective and reduced bacterial numbers by ~1 × 104 CFU/mL within 2 h. In
comparison, other studies have shown lower reductions in bacterial numbers, where a three-
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phage [48] and a six-phage cocktail [12] reduced Salmonella numbers by ~1 × 102 CFU/mL.
Our study highlights the importance of assessing different phage combinations to deter-
mine the optimal combinations to reduce the target pathogen.
After identifying the best phage cocktails in vitro, the efficacy of a two, three and
four phage cocktails was tested in the in vivo larvae infection model. Our data showed that
there was a correlation between in vitro and in vivo data as again the two-phage cocktail
SPFM10-SPFM14 was the most efficient at reducing Salmonella numbers. The cocktail was
more efficacious when it was administered prophylactically, where larvae survival rates
after 72 h were 90% versus 72%, when the phage cocktail was administered concurrently
with the larvae challenge. Furthermore, Salmonella was not isolated from over 65% of
larvae, under either treatment regimen in larvae administered the two-phage cocktail,
suggesting pathogen clearance. The fact that the prophylactic treatment was more effective
than concurrent treatment is in keeping with other studies that found similar results
in C. difficile [49] and Pseudomonas [34]. The increased phage efficacy with prophylactic
treatment could be due to phages being distributed throughout the haemolymph before
bacterial cells are introduced, which limits bacterial colonisation and contributes to larvae
survival [34]. In contrast, in the co-infection model, the bacterial cells have more of an
opportunity to colonise the haemolymph and thus the phages are less effective. Salmonella
colonies isolated post-exposure were still sensitive to phage infection, as has been reported
in other larvae challenge model studies [32,49–51]. However, it could also be possible
the low challenge dose of 105 CFU/larva used was insufficient to isolate phage resistant
mutants. Moving forward resistant strains could have been potentially isolated if a higher
dose of 107 CFU/mL (as used in the killing assays) was used. Overall, our data on the
efficacy of prophylactic phage treatment suggest it could be an important and testable
intervention point to prevent bacterial infection in pigs.
A major message from this work is that there are considerable phenotypic differences
(pH and temperature stability) between the phages despite them sharing 99% ANI. This
observation is of fundamental importance to the way in which we understand phage
biology and the strikingly few SNPs with distinct phenotypes will ultimately allow a better
mechanistic understanding of these phages. Here, we discuss the types of the genetic
changes and how they may be linked to phenotype.
The most striking phenotypic difference between the phages is heat stability. It is
currently unclear why SPFM10 is more heat stable than the other phages tested. One
possible explanation would be the environment from which they are isolated; however,
it should be noted that SPFM4 and SPFM10 were isolated from the same source (food
processing plant in Essex, UK), and yet their heat stability differs significantly. Therefore, it
could be concluded that the evolution of the heat resistant phenotype is more specialised
and complex than simply reflecting the environmental source.
Through SNP analysis, we identified that the heat stable phage SPFM10 has only one
SNP difference to the heat labile phage SPFM14 (at 70,890 bp, locus tag SPFM10_00081), the
same difference is seen between SPFM10 and SPFM2, 4, 17 and 19. Thus, we predict a single
amino acid change could determine increased heat resistance. The function of this protein
(locus tag SPFM10_00081) is unknown but the gene encoding it was previously identified
to be under positive selection [35]. The protein was analysed for predicted secondary and
tertiary structure using the programs JPred [52], Phmmer [53] and Phyre2 [54]. Phyre2
analysis identified a domain within the protein with similarity to an Fibronectin type III
(FN3)/FN3-like domain (with 94–96% confidence). These domains are commonly found in
eukaryotes and bacterial extracellular glycohydrolases [55,56]. FN3 domains are thought
to contribute to bacterial recognition by facilitating binding to bacterial surface adhesion
proteins [57]. Within phages, these domains are typically found within structural proteins of
tailed dsDNA phages. For example, an analysis by Fraser et al. showed that FN3 domains
were predominantly found in baseplate wedge initiator proteins, major tail proteins, and
tail fibre proteins [58]. We hypothesise this protein is therefore a structural protein, likely
to be linked with the tail or baseplate wedge. The conservative amino acid substitution
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(Thr to Ser) observed between the heat stable and heat labile versions of this protein is
shown to elongate a predicted β-strand. Future structural studies of this protein and its
variants could confirm whether the increased stability is directly linked to the protein and
its secondary structure, as predicted from virtual models, or elucidate other causes for
thermostability including altered interactions with other parts of the phage capsid/tail or
even with bacterial surface adhesion proteins.
Both SPFM17 and SPFM10 have increased stability compared to other phages, yet
only SPFM10 has a mutation of A -> T at position 70,890. Therefore, it is likely that one
or more of the four other mutations in SPFM17 also provide increased resistance to heat
compared to other phages, but not to the same degree as the mutation at position 70,890 bp.
It should also be noted that the cost of heat resistance comes at the cost of increased
sensitivity to acidic pH. Further work is needed to ultimately confirm which SNPs are
linked to phenotypic differences and establish their mechanistic basis of action. Another
study recently demonstrated that single nucleotide variations can increase the temperature
stability of phages infecting Pectobacterium and Ralstonia [59], which further support our
results that SNPs in key genes can have dramatic phenotypic effects.
The marked phenotypic differences of closely related phages were unexpected, with a
single-base mutation the most likely cause of increased temperature stability and decreased
pH stability. The likely single-base change that causes drastic phenotypic differences is an
important consideration when using phages for practical purposes in pathogen control and
treatment. There is limited information on the rates of mutation in bacteriophages with
estimates for dsDNA phages of between 1.88 × 10−4 and 1 × 10−7 substitution rate per site
per year [60]. For genomes of ~250 kb this equates to between ~0.24 and 45 substitutions
per year [61]. How this rate of substitution holds true for this phage type during mass
production is unknown, but it is clear that the heat stable phenotype should be assessed
during production to ensure it is still present. Quality control procedures to monitor
differences in batches would be required. As a scenario where a small proportion of the
population have a new fixed mutation, leads to differences in efficiency between batches
which could be negative or positive.
4. Materials and Methods
4.1. Bacterial Strains and Growth Conditions
Two Salmonella enterica subsp. Enterica serovar Typhimurium strains were used in
this study: SL1344 (accession number FQ312003), a laboratory reference strain, and strain
S01160-12 phage type DT193. The MDR Salmonella strain S01160-12 was isolated by the
Animal Plant Health Agency, UK from an infected pig in 2012 [38] and is resistant to antibi-
otics: tetracycline, neomycin, ampicillin, sulfamethoxazole, chloramphenicol, gentamicin,
streptomycin, compound sulphonamide and apramycin. Both Salmonella isolates were
routinely grown on Xylose Lysine Deoxycholate (XLD) agar (Oxoid, Basingstoke, UK) for
18 h at 37 ◦C. To prepare liquid cultures, strains were inoculated in NZCYM broth (Melford
Biolaboratories Ltd., Ipswich, UK) and grown for 18 h at 37 ◦C at 100 rpm.
4.2. Phages and their Genome Accession Numbers
Phages SPFM2, SPFM4, SPFM10, SPFM14, SPFM17 and SPFM19 from our Salmonella
jumbo phage collection were used in this study [35]. Phages were previously deposited
to European Nucleotide Archive and their GenBank accession numbers are: SPFM2
(LR535921.1), SPFM4 (LR535902.1), SPFM10 (LR535908.1), SPFM14 (LR535912.1), SPFM17
(LR535914.1) and SPFM19 (LR535916.1).
4.3. Phage Propagation and Titration
Phages were propagated via liquid propagation in NZCYM media as previously
described in detail [35].
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4.4. One-Step Growth Assay
A previously described method was followed [62]. Exponential cultures of SL1344
at optical density (OD600) 0.2, with cell densities of 107 CFU/mL were mixed with phage
at a multiplicity of infection (MOI) of 0.01. Phages were allowed to adsorb for 5 min at
37 ◦C and unbound phages were removed by centrifuging at 4200× g for 10 min. The
bacterial pellet was re-suspended with NZCYM broth and incubated at 37 ◦C with shaking
(100 rpm). Aliquots were taken every 10 min for 1.5 h and the small drop plaque assay
method was used to determine the PFU/mL count [63]. Three biological replicates were
performed each with three technical repeats.
4.5. Phage Receptor Analysis
Professor Sangryeol Ryu (Seoul National University, Seoul, South Korea) kindly sent
us S. Typhimurium SL1344 strains with deletions in the flagellar production gene (SL1344
flgK); the gene that encodes vitamin B12 uptake outer membrane protein (SL1344 butB); and
an RfaL ligase mutant the prevents LPS production (SL1344 rfaL) [37]. To determine if the
phages use either of the three as their host receptor, phage lysates at titres ~5 × 109 PFU/mL
were diluted 10-fold and plated on the mutant strains using the small drop plaque assay
method [63]. For the efficiency of plating (EOP) study three biological replicates were
performed each with three technical repeats and EOP was compared to the wild-type
strain SL1344.
4.6. Temperature and pH Stability Assays
Heat stability of phage lysate (volume 500 µL in NZCYM broth) at titre ~109 PFU/mL
was tested by exposing lysates to a range of temperatures of 4, 10, 20, 30, 40, 50, 60, 70, 80,
90 and 100 ◦C for one hour using a thermocycler (Bioline, UK). For pH stability, 100 µL
of phage lysate was added to 900 µL of SM buffer at pH of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13 and 14. After this, the phage samples were incubated at room temperature for one
hour. To determine phage titre after exposure to different temperatures and pH, the phage
lysate was immediately serially diluted 10-fold and the small drop plaque assay method
was used on LB 1% (w/v) agar plates with bacterial lawns of SL1344 [63]. Final phage titres
were expressed as PFU/mL and three biological replicates were performed, each with three
technical repeats.
4.7. Single-Nucleotide Polymorphism (SNP) and Indels Analysis
SNPs were detected by aligning reads against the reference genome SPFM10 with
minimap2 using the short read settings. Resultant BAM files were processed with samtools
v1.10 [64] to produce a mpileup file, used as input for VarScan v2.3 [65]. SNPs were called
with ‘–min-var-freq 0.9, –min-avg-qual 20, –p-value’, with other settings left as default.
4.8. In Vitro Bacterial Killing Assay with Individual Phages and Phage Cocktails
Killing assays were conducted with individual phages and with different phage
cocktail combinations (Table 4). The S. Typhimurium strain S01160-12 was chosen for
these experiments as the strain is a representative MDR circulating in pig farms and all
six phages are able to lyse the strain with comparable EOP to their host strain SL1344 [35].
For all killing assays, cultures of S01160-12 were grown to an optical density (OD600) of
0.2 (~107 CFU/mL) at which point phage or phages were added at a MOI of 100 (phages
were mixed at equal volumes at a final titres of 109 PFU/mL). All killing assay experiments
included a bacterial only control. Both the control and test samples were incubated at 37 ◦C
with shaking (100 rpm), and aliquots were taken at the following time points: 0, 1, 2, 3, 4,
5 and 6 h. For each time point, bacterial concentrations (CFU/mL) were determined on
LB 1% agar plates and phage concentrations (PFU/mL) by the small drop plaque assay
method [63].
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4.9. Testing Efficacy of Phage Cocktails in the In Vivo Galleria Mellonella Infection Model
4.9.1. Preparation of Galleria Mellonella
Larvae were purchased from Live Food UK Ltd. (Rooks Bridge, UK), stored at 4 ◦C and
used within two days. For all in vivo experiments larva that weighed approximately 0.25 to
0.30 g were chosen and were surface sterilised with cotton swabs dipped in 70% ethanol.
4.9.2. Salmonella Infected G. mellonella Treated with Phage Cocktails
For all larvae phage therapy studies, previously described methods were used [32,38,49].
Both the Salmonella strain S01160-12 (LD50 dose of 105 CFU) and phage cocktails at a fi-
nal concentration of 107 PFU (MOI 100 and phages were mixed at equal volumes) were
administered to the larvae via the oral route using a Hamilton syringe pump. The strain
S01160-12 was prepared by growing a liquid culture of S01160-12 overnight. The concen-
tration of the cells in the culture was ~109 CFU/mL and the culture was centrifuged at
4200× g for 10 min. The supernatant was discarded; the pellet was resuspended in 0.1 M
phosphate-buffered-saline (PBS) and centrifuged at 4200× g for 10 min. The supernatant
was discarded again; the pellet was resuspended in PBS and diluted 10-fold in PBS to
107 CFU/mL. Larvae were administered 10 µL of bacterial culture, which equated to a final
concentration of ~105 CFU.
Phage cocktails were either administered prophylactically, 1 h prior to Salmonella
infection or simultaneously with Salmonella (the regimens are detailed in Table 4. The
latter method was conducted by first injecting larvae with Salmonella and then rapidly
infecting larvae with the phage cocktail in a separate injection. For both regimens phage
cocktails were administered at an MOI of 100 (final concentration of 107 PFU). Larvae were
incubated at 37 ◦C for 3 days. Every 24 h, survival of larvae was monitored, and larvae
were sacrificed to determine CFU and PFU counts. For this, larvae were stored at −20 ◦C
for 3 h, dissected to remove their haemolymph, which was suspended in 1 mL of PBS and
vortexed for 30 s. To determine the PFU counts the samples were centrifuged at 5000× g
for 5 min. The supernatant was then diluted 10-fold and titred by the small drop plaque
assay method [63]. To determine the CFU counts the suspension was diluted with 10-fold
dilutions and spot tested on XLD agar plates. For both the CFU and PFU counts, three
technical repeats were conducted.
For each group listed in Table 2, 60 larvae were used per group and every 24 h 20 larvae
were assessed for survival and dissected. If the larvae were unresponsive to touch and
changed colour from light brown to black they were considered dead. Control larvae
groups were included in all experiments and the groups were: healthy larvae; larvae only
administered 107 PFU phages via the oral route; larvae only administered with 105 CFU
S01160-12 via the oral route; and larvae administered PBS via the oral route (Table 2). In all
control groups 60 larvae were used in total and 20 were scarified every 24 h to determine
CFU and PFU counts in their haemolymphs.
4.9.3. Larvae Survival Curves and Statistical Analysis
Three biological replicates were conducted for all larvae experiments, and survival
data were plotted using Graphpad Prism version 6 (GraphPad Software Inc., San Diego,
CA, USA) with the Kaplan–Meier method. The differences in survival rates were assessed
using the Log-rank (Mantel-Cox) test.
4.9.4. Testing Development of Phage Resistance In Vivo
Salmonella colonies recovered from the larva’s haemolymph in the phage treatment
groups were screened to determine if resistance had developed to the respective cocktails
they were exposed to. Salmonella colonies recovered from dead and alive larvae were
picked and streaked on XLD agar plates. Plates were incubated at 37 ◦C for 18 h and then
re-streaked onto XLD agar plates. The process was repeated three times. In total 60 colonies
from each phage treatment were picked (Supplementary Tables S4–S6).
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Salmonella colonies were inoculated into NZCYM broth and grown for 2 h at 37 ◦C at
100 rpm, prior to being used to make lawns to determine their sensitivity to phages via spot
tests. Then, 10 µL of phages was spotted in triplicate at a concentration of 108 PFU/mL.
Further resistant studies were conducted by randomly selecting 10/60 colonies from each
phage treatment and determining EOP of the phages on these strains compared to the wild-
type strain S01160-12. In the EOP studies, phage lysates at a concentration of 108 PFU/mL
were diluted 10-fold and plated using the small drop plaque assay method [63]. For all
EOP studies and spot tests, three biological and three technical replicates were conducted.
EOP values were compared to EOP of the phages on the wild-type strain.
4.10. Statistical Analysis
Data presented and discussed in this study are average values from three biological
replicates, of which each had three technical repeats. To determine the significance of
bacterial and phages counts between treatments student t-tests were conducted. Significant
differences (p values) between treatments were determined by comparing the results in the
test group with the results obtained for the correspondent control group for each different
time point or condition tested. Values of p < 0.05 were considered as statistically significant
(* p < 0.05, ** p < 0.01 and *** p < 0.001).
5. Conclusions
In this study, we found that genetically similar Salmonella phages have very different
phenotypes even though SNP analysis highlighted one to five SNP differences. Future
genetic and biochemical work in our laboratory will determine how these SNPs relate to
the phenotypic differences between the phages. We showed the surprising observation
that the genetically similar phages are more effective as two-phage cocktails rather than as
single phages or three or four phage cocktails. We also show how a natural set of phages
can act as a starting point to pinpoint specific genes in order to unravel the function of key
phage proteins that determine phenotype.
6. Patents
The SPFM Salmonella phages are part of a Leicester patent, pending. United Kingdom
Patent Application 1815483.1 and international application number PCT/GB2019/052695.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/ph15010058/s1, Supplementary Table S1: Latent period and
burst sizes of SPFM phages. Supplementary Table S2: Protein sequences of the genes in which
SNPs were identified in the genome of SPFM10 when compared to phage genomes SPFM2, 4, 14,
17 and 19. Supplementary Table S3: Average Salmonella counts following infection with phage or
phage cocktail in killing assay experiments. Supplementary Table S4: sensitivity of colonies picked
after being exposed to the two-phage cocktail SPFM10-SPFM14 in the challenge larvae experiments,
to individual phages within the cocktail. Supplementary Table S5: sensitivity of colonies picked
after being exposed to the three-phage cocktail SPFM4-SPFM10-SPFM19 in the challenge larvae
experiments, to individual phages within the cocktail. Supplementary Table S6: sensitivity of
colonies picked after being exposed to the four-phage cocktail SPFM2-SPFM10-SPFM14-SPFM19 in
the challenge larvae experiments, to individual phages within the cocktail.
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